Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease

Autor: Nejc Piko, Sebastjan Bevc, Radovan Hojs, Robert Ekart
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Pharmaceuticals, Vol 17, Iss 4, p 418 (2024)
Druh dokumentu: article
ISSN: 17040418
1424-8247
DOI: 10.3390/ph17040418
Popis: Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje